This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON&BIRD LLP

101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000

> 704-444-1000 Fax: 704-444-1111

SEP 0 3 2002 GROUP 1600

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

DATE: August 30, 2002

TO: Ex. T. Strzelecka – U.S. Patent and Trademark Office – Group #1637

FROM: Paul F. Pedigo

USSN - 09/678,997 - OFFICIAL DOCUMENT

NO. OF PAGES: 15 OPERATOR:

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY ME IMMEDIATELY AT

USER CODE:

RIPPG

FAX NUMBER:

703-305-3014

CLIENT/MATTER:

034848/194868

REQUESTED BY:

Grace Rippy 1175

VOICE NUMBER:

703-308-0196

Attorney's Docket No. 34848/194868

PATENT

RESPONSE UNDER 37 C.F.R. § 1.116 **EXPEDITED PROCEDURE - EXAMINING GROUP 1637**

In re:

Bentley et al.

Confirmation No.: 4896

Appl. No.:

09/678,997

Group Art Unit: 1637

Examiner:

T. Strzelecka

Filed: For:

October 4, 2000 POLYMER STABILIZED NEUROPEPTIDES

BOX AF Commissioner for Patents Washington, DC 20231

Sir:

Transmitted herewith is an AMENDMENT AFTER FINAL in the above-identified patent application.

	Applicant claims small entity status.	See 37 CFR	§1.27.
Ĺ	No additional fee is required.		

The fee has been calculated as shown below:

(COL. 1)			(COL. 3)	COL. 3) SMALL	ENTITY	OTHER THAN A SMALL ENTITY	
	EMAINING IENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT.	OR RATE	ADDIT. FEE
TOTAL	* 27	** 20	= 7	X 9=	S	X18=	\$ 126
INDEP	* 6	*** 3	= 3	X42=	S	X84=	\$ 252
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+140=	\$	+280=	s
					ΓAL FEE \$	OR TOTAL	\$ 378

If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior Amendment or the number of claims originally filed.

	1 of a prior Amendment or the number of claims originally filed.	e 69678997
\boxtimes	Please charge my Deposit Account No. 16-0605 in the amount of \$378.00 LIGOSOB 16866 A check in the amount \$ to cover the additional fee is enclosed EWILL INCOME.	

In re: Bentley et al. Appl. No. 09/678,997 Filed: October 4, 2000

Atty. Dock. No.: 34848/194868

Page 2_

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-0605.

Any additional filing fees required under 37 C.F.R. § 1.16 for the presentation of extra claims.

Any patent application processing fees under 37 C.F.R. § 1.17.

Respectfully submitted,

Paul F. Pedigo

Registration No. 31,650

CUSTOMER NO. 00826 ALSTON & BIRD LLP

 \boxtimes

Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Charlotte Office (704) 444-1000
Fax Charlotte Office (704) 444-1111

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office at Fax No. 703-305-3014on the date shown below.

Grace R. Rippy

(Type or print name of person signing certification.)

Signature

Date

Attomey's Docket No. 34848/194868

PATENT

RESPONSE UNDER 37 C.F.R. 1.116 - EXPEDITED PROCEDURE - EXAMINING GROUP 1637

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Bentley et al.

Confirmation No.: 4896

Appl. No.:

09/678,997

Group Art Unit: 1637

Filed:

October 4, 2000

Examiner:

T. Strzelecka

For:

POLYMER STABILIZED NEUROPEPTIDES

August 30, 2002

BOX AF Commissioner for Patents Washington, DC 20231

AMENDMENT AFTER FINAL ACTION PURSUANT TO 37 C.F.R. § 1.116

Sir:

In response to the Final Office Action mailed May 31, 2002, please enter the following amendments:

In the Claims:

30. (Amended) A substantially hydrophilic conjugate comprising an analgesic peptide that is either biphalin or [D-Pen2, D-Pen5] enkephalin (DPDPE) covalently linked to a water soluble, nonpeptidic polymer selected from the group consisting of poly(ethylene glycol), copolymers of ethylene glycol and propylene glycol, poly(vinyl alcohol), poly(alkylene oxides), poly(oxyethylated polyols), poly(olefinic alcohols), poly(acryloyl morpholine), poly(vinyl pyrrolidone), poly(oxazoline), dextran, poly(hydroxyethyl methacrylate), wherein said conjugate, when administered into the blood circulation of a mammal, can transport across the blood-brain barrier.